Accordingly, in our quantitative approach, we found increased levels of tau binding in early‐stage tau regions in tau‐PET‐negative AD patients in ADNI only, and minimally in late regions, indicating that these individuals tend to show higher levels of tau in early‐stage regions, which may be missed using the VR method. The gene discussed is MAPT; the disease is Alzheimer disease.